TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
$IBRX · biology stocks are the next frontier
now playing · $IBRX
$IBRX···bullish· high· posunknown
ALC Magic likens ImmunityBio to the Nvidia of biotech for its IL-15 platform
ImmunityBio is not a drug but a platform: its IL-15 super-agonist reboots the immune system by boosting T-cells and NK cells, allowing specific solutions to be built on top. Compa…
$IBRX···bullish· high· posantonio linares
ImmunityBio's IL-15 superagonist reboots immune system as foundational platform for longevity
ImmunityBio's IL-15 superagonist expands T and NK cell counts and cytotoxicity, creating a platform where engineered cells can be layered on top to target specific pathogens and t…
$HIMS···bullish· high· posunknown
ALC Magic doubles down on HIMS: $2,000 share price target by 2030
The market sees HIMS as a GLP-1 company, but it is the D2C layer that owns the patient touchpoint; it will be the ontology (Costco for biomarkers) on which the entire longevity-as…
$NAUT···bullish· mediumunknown
Nautilus: Voyager platform maps 10 billion proteins per run for Alzheimer's and beyond
A unique single-molecule read of the proteome built on iterative mapping technology that is hard to replicate; an inflection in 12-24 months as it jumps from neurodegenerative dis…
$NAUT···bullish· mediumantonio linares
Nautilus Voyager platform enables single-molecule proteomic read at scale for disease interception
Nautilus's iterative mapping technology can read up to 10 billion intact proteins per run, providing an exhaustive proteoform-level map that reveals the proteomic dysfunction unde…
$TEM···bullish· mediumunknown
Tempus AI wins on scale: oncology data that is hard to replicate and embedded in hospitals
Molecular oncology reads correlated with clinical outcomes; the edge comes from hard-to-replicate hospital integration. Trade-off vs. Caris: Tempus operates at greater scale with…
$TEM···bullish· mediumantonio linares
Tempus AI builds oncology molecular ontology via select gene panel tests at hospital scale
Tempus integrates molecular cancer data from select gene panels with clinical outcomes across hospital networks, creating a proprietary dataset that trains AI to predict optimal p…
$CAI···bullish· mediumantonio linares
Caris Life Sciences reads full exome for deeper oncology molecular data and cash-generating operations
Caris reads the full exome rather than a select panel, enabling re-mining of proprietary data as new cancer biomarkers are discovered, and is already producing cash flow, potentia…
$CAI···bullish· mediumunknown
Caris Life Sciences is already cash-generative with deeper genetic reads than Tempus
Caris reads the full exome (Tempus only a select genetic panel), which will let it re-mine its proprietary data as new biomarkers are discovered. A depth-vs-scale trade-off; it is…
$RXRX···bullish· mediumunknown
Recursion: a generative engine that maps atoms to biology and rescues toxic drugs
A physics-plus-chemistry AI trained on massive wet-lab data; a demonstrated ability to take drugs abandoned for toxicity and refine them to lower toxicity and improve efficacy. Th…
$RXRX···bullish· mediumantonio linares
Recursion maps physics and chemistry to biology via wet-lab AI to rescue toxic failed drugs
Recursion's massive wet-lab dataset trains physics and chemistry AI models that understand how atomic interactions emerge into biology, allowing them to fine-tune abandoned toxic…
$HIMS···bullish· highantonio linares
Hims & Hers owns the D2C distribution ontology with aligned incentives for longevity as a service
HIMS controls the direct consumer relationship and HIMS Labs biomarker infrastructure, with business incentives aligned to keeping customers healthy over time rather than profitin…
$INKT···bullish· mediumantonio linares
MiNK Therapeutics leverages iNKT cells targeting lipid antigens for low-toxicity dense-tumor penetration
MiNK's invariant NKT cells recognize lipid antigens (which evolve slower than peptides), enabling low-toxicity, off-the-shelf cell therapy that natively penetrates dense stromal t…
$NGEN···bullish· mediumantonio linares
NervGen's NVG-291 peptide releases the brake on axonal repair for nervous system regeneration
NervGen's peptide NVG-291 combines a cell-penetrating sequence with a ligand-blocking domain that inhibits the receptor interaction preventing nerve repair, potentially creating a…
$PARABILIS-MEDICINESbullish· mediumantonio linares
Parabilis helicon technology drugs the undruggable 80% of intracellular flat-surface protein targets
Parabilis's stapled helical peptides (helicons) maintain structure to penetrate cell membranes and bind flat intracellular protein surfaces, addressing the 80% of disease-driving…
$INKT···bullish· mediumunknown
MiNK Therapeutics: an abandoned third arm of the immune system with low toxicity
It leverages iNKT (invariant) cells, which are independent of the MHC peptide complex; low allogeneic toxicity, native to dense tissue (pancreas, liver) and cytotoxic. Complementa…
$DUOL···bullish· mediumunknown
ALC Magic vindicates Duolingo as a case study in ontology velocity against the AI panic
Despite the winter's fear that AI would kill Duolingo, DAU and free cash flow per share are rising vertically. An example of how proprietary data plus network effects beat the gen…